CAR-T | Solid Tumors Success | When? - 2021 World Medical Innovation Forum
May 2–4, 2022

CAR-T | Solid Tumors Success | When?

CAR-T | Solid Tumors Success | When?

Wednesday, May 19, 2021

3:30 PM – 3:55 PM
Hot Topics

The potential application of CAR-T in solid tumors will be a game-changer if it occurs. The panel explores the prospects of solid tumor success and what the barriers have been. Questions include:

  •  How would industry and investor strategy for CAR-T and solid tumors be characterized? Has it changed in the last couple of years?
  •  Does the lack of tumor antigen specificity in solid tumors mean that lessons from liquid tumor CAR-T constructs will not translate well and we have to start over?
  •  Whether due to antigen heterogeneity, a hostile tumor micro-environment, or other factors are some specific solid tumors more attractive opportunities than others for CAR-T therapy development?
  •  Given the many challenges that CAR-T faces in solid tumors, does the use of combination therapies from the start, for example, to mitigate TME effects, offer a more compelling opportunity.
Oladapo Yeku, MD, PhD
  • Clinical Assistant in Medicine, MGH
Jennifer Brogdon
  • Executive Director, Head of Cell Therapy Research, Exploratory Immuno-Oncology, NIBR
Knut Niss, PhD
  • CTO, Mustang Bio
Barbra Sasu, PhD
  • CSO, Allogene
Jay Short, PhD
  • Chairman, CEO, Cofounder, BioAlta, Inc.
  • Q&A

    04:00 PM – 04:15 PM

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA